Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Epstein-barr virus infection? 203 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 203 reports of Epstein-barr virus infection have been filed in association with INFLIXIMAB (Renflexis). This represents 0.1% of all adverse event reports for INFLIXIMAB.

203
Reports of Epstein-barr virus infection with INFLIXIMAB
0.1%
of all INFLIXIMAB reports
34
Deaths
88
Hospitalizations

How Dangerous Is Epstein-barr virus infection From INFLIXIMAB?

Of the 203 reports, 34 (16.7%) resulted in death, 88 (43.3%) required hospitalization, and 26 (12.8%) were considered life-threatening.

Is Epstein-barr virus infection Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 203 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Epstein-barr virus infection?

TACROLIMUS (1,252) MYCOPHENOLATE MOFETIL (1,191) PREDNISONE (815) CYCLOSPORINE (793) METHOTREXATE (749) CYCLOPHOSPHAMIDE (629) PREDNISOLONE (592) RITUXIMAB (575) FLUDARABINE (476) METHYLPREDNISOLONE (443)

Which INFLIXIMAB Alternatives Have Lower Epstein-barr virus infection Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Epstein-barr virus infection Reports All Drugs Causing Epstein-barr virus infection INFLIXIMAB Demographics